Vistagen Therapeutics Files 8-K on Shareholder Vote Matters
Ticker: VTGN · Form: 8-K · Filed: Aug 28, 2024 · CIK: 1411685
| Field | Detail |
|---|---|
| Company | Vistagen Therapeutics, Inc. (VTGN) |
| Form Type | 8-K |
| Filed Date | Aug 28, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, 8-k
Related Tickers: VTGN
TL;DR
VTGN filed an 8-K for shareholder vote matters. Expect corporate action.
AI Summary
Vistagen Therapeutics, Inc. filed an 8-K on August 28, 2024, reporting on matters submitted to a vote of security holders as of August 26, 2024. The filing details the company's corporate structure, including its state of incorporation (Nevada) and principal executive offices in South San Francisco, California.
Why It Matters
This filing indicates that Vistagen Therapeutics is engaging in corporate actions requiring shareholder approval, which could impact the company's future direction and governance.
Risk Assessment
Risk Level: low — This is a routine filing reporting on corporate governance matters and does not disclose new financial or operational risks.
Key Numbers
- 000-54014 — Commission File Number (Identifies the company's SEC filing history.)
- 20-5093315 — IRS Employer Identification Number (Company's tax identification number.)
Key Players & Entities
- Vistagen Therapeutics, Inc. (company) — Registrant
- Nevada (jurisdiction) — State of incorporation
- South San Francisco, California (location) — Principal executive offices
- August 26, 2024 (date) — Date of earliest event reported
- August 28, 2024 (date) — Date of report
FAQ
What specific matters were submitted to a vote of Vistagen Therapeutics' security holders?
The filing states it is a 'CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934' and reports 'Submission of Matters to a Vote of Security Holders' as of August 26, 2024. However, the specific details of these matters are not provided in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this filing was on August 26, 2024.
What is Vistagen Therapeutics, Inc.'s state of incorporation?
Vistagen Therapeutics, Inc. is incorporated in Nevada.
Where are Vistagen Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 343 Allerton Ave., South San Francisco, California.
What is the company's telephone number?
The company's telephone number is (650) 577-3600.
Filing Stats: 780 words · 3 min read · ~3 pages · Grade level 10.1 · Accepted 2024-08-28 16:07:17
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VTGN Nasdaq Capital Marke
Filing Documents
- vtgn20240827_8k.htm (8-K) — 37KB
- 0001437749-24-027943.txt ( ) — 166KB
- vtgn-20240826.xsd (EX-101.SCH) — 3KB
- vtgn-20240826_def.xml (EX-101.DEF) — 11KB
- vtgn-20240826_lab.xml (EX-101.LAB) — 15KB
- vtgn-20240826_pre.xml (EX-101.PRE) — 11KB
- vtgn20240827_8k_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders On August 26, 2024, Vistagen Therapeutics, Inc. (the " Company ") held its 2024 Annual Meeting of Stockholders (the " 2024 Annual Meeting "). At the 2024 Annual Meeting, as set forth below, the Company's stockholders: (i) elected each of the seven director nominees to the Company's Board of Directors (the " Board "); (ii) approved, on an advisory basis, the compensation paid to the Company's named executive officers; and (iii) ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending March 31, 2025. The matters voted upon at the 2024 Annual Meeting and the results of the voting by the Company's stockholders are as follows: Proposal No. 1 – Election of Directors For Withheld Margaret M. FitzPatrick, M.A. 12,431,830 2,263,438 Ann M. Cunningham, MBA 11,782,124 2,913,144 Joanne Curley, Ph.D. 12,805,113 1,890,155 Jerry B. Gin, Ph.D., MBA 13,923,175 772,093 Mary L. Rotunno, J.D. 12,777,661 1,917,607 Jon S. Saxe, J.D., LL.M. 14,218,617 476,651 Shawn K. Singh, J.D. 14,540,841 154,427 Members of the Board are elected by a plurality of the votes cast. Accordingly, each of the director nominees named above was elected to serve on the Board until the Company's 2025 Annual Meeting of Stockholders, or until her or his successor is elected and qualified. Proposal No. 2 – Non-Binding Advisory Vote to Approve Executive Compensation (Say-on-Pay Proposal) For Against Abstain Votes 13,758,902 842,393 93,973 The vote required to approve the non-binding advisory vote on executive compensation paid to the Company's named executive officers was the affirmative vote of a majority of the votes cast on the proposal. Accordingly, the Company's stockholders approved, on a non-binding advisory basis, the compensation paid to the Company's named executive officers, as reported in the Company's definitive proxy stat
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Vistagen Therapeutics, Inc. Date: August 28, 2024 By: /s/ Shawn K. Singh, J.D. Shawn K. Singh Chief Executive Officer